Zwanikken G J, Oei T T, Kimya S, Amery W
Acta Psychiatr Belg. 1976 May;76(3):467-9.
The trial involved 69 female, long-stay inpatients of the Voorburg mental hospital, of a median age of 50 years. Two groups were formed at the start of the trial. The first group (51 patients) on a maintenance therapy with orphenadrine, were now put on oral dexetimide. Individually adapted dosages ranged from 0.5 to 1.5 mg daily. The control group (18 patients) of antiparkinsonian agents did not take any in the course of the study either. After three and six months (end of trial) biochemical and haematologic parameters were assessed. Clinical evaluation of extrapyramidal symptoms was made in the dexetimide group. All patients of the control group and 47 of the dexetimide group completed the trial. Both groups were shown to be comparable with regard to all parameters. Statistical analysis showed significant improvement in dexetimide-patients with regard to gross motor tremor, facial inexpressiveness, parkinsonian gait (after two weeks) + dyskinesia (after six months).
该试验涉及福尔堡精神病院的69名长期住院女性患者，中位年龄为50岁。试验开始时分为两组。第一组（51名患者）原接受奥芬那君维持治疗，现改为口服右苯甲酰胺。个体化调整后的剂量范围为每日0.5至1.5毫克。对照组（18名患者）在研究过程中未服用任何抗帕金森病药物。在三个月和六个月（试验结束时）评估生化和血液学参数。对右苯甲酰胺组进行锥体外系症状的临床评估。对照组的所有患者以及右苯甲酰胺组的47名患者完成了试验。两组在所有参数方面均具有可比性。统计分析表明，右苯甲酰胺治疗的患者在粗大运动震颤、面部表情缺失、帕金森步态（两周后）+运动障碍（六个月后）方面有显著改善。
